Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Appointed director
ROCKET PHARMACEUTICALS, INC. (RCKT) Create: Alert

All | News | Filings
Date FiledTypeDescription
10/02/2023 8-K Quarterly results
04/04/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
03/10/2023 8-K Regulation FD Disclosure  Interactive Data
02/27/2023 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits  Interactive Data
Docs: "CRANBURY, N.J. – Feb. 27, 2023"
02/07/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "CRANBURY, N.J. – Feb. 7, 2023"
01/09/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Investor Presentation of Rocket Pharmaceuticals, Inc",
"CRANBURY, N.J. – Jan. 9, 2023 – Rocket Pharmaceuticals, Inc. , a leading late-stage biotechnology company advancing an integrated and sustainable pipeline of genetic therapies for rare childhood disorders with high unmet need, today announces the addition of RP-A601 to Rocket’s cardiac gene therapy portfolio as well as anticipated highlights for the year ahead across the Company’s world-class pipeline of lentiviral and AAV gene therapy programs targeting rare hematologic and cardiovascular diseases. These announcements and anticipated highlights will be presented at the 41st Annual J.P. Morgan Healthcare Conference today at 2:15 p.m. PT by Gaurav Shah, M.D., Chief Executive Officer, Rocket Pharma."
12/22/2022 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "CRANBURY, N.J. – Dec. 22, 2022 – Rocket Pharmaceuticals, Inc. , a leading late-stage biotechnology company advancing an integrated and sustainable pipeline of genetic therapies for rare childhood disorders with high unmet need, today announces updates from the Company's end-of-Phase 1 meeting with the U.S. Food and Drug Administration regarding RP-A501, the Company's investigational adeno-associated virus -based gene therapy for Danon Disease. During the meeting, Rocket reviewed the positive Phase 1 dataset with the FDA and proposed a study design and endpoints for ongoing clinical development of the investigational gene therapy."
12/01/2022 8-K Quarterly results
11/03/2022 8-K Quarterly results
10/04/2022 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits  Interactive Data
Docs: "Underwriting Agreement, among Rocket Pharmaceuticals, Inc. and Morgan Stanley & Co. LLC, J.P. Morgan Securities LLC and SVB Securities LLC, as representatives of the several underwriters named in Schedule A thereto",
"Opinion of Goodwin Procter LLP"
10/03/2022 8-K Quarterly results
09/20/2022 8-K Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Agreement and Plan of Merger, by and among Parent, the Company, Merger Sub I and Merger Sub II",
"Form of Parent Voting Agreement",
"Form of Company Voting Agreement",
"Rocket Pharmaceuticals to Acquire Renovacor,"
09/09/2022 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Investor Presentation of Rocket Pharmaceuticals, Inc"
08/08/2022 8-K Quarterly results
06/15/2022 8-K Quarterly results
03/11/2022 8-K Quarterly results
02/28/2022 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits  Interactive Data
Docs: "Opinion of Goodwin Procter LLP",
"Sales Agreement, by and between the Company and Cowen and Company, LLC"
02/24/2022 8-K Quarterly results
11/03/2021 8-K Quarterly results
Docs: "CRANBURY, NJ – November 3, 2021"
08/30/2021 8-K Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Regulation FD Disclosure, Financial Stat...
Docs: "Securities Purchase Agreement, between Rocket Pharmaceuticals, Inc. and the purchaser party thereto",
"Registration Rights Agreement, between Rocket Pharmaceuticals, Inc. and the purchaser party thereto",
"Rocket Pharmaceuticals Announces $26.4 Million Private Placement"
08/09/2021 8-K Quarterly results
06/21/2021 8-K Submission of Matters to a Vote of Security Holders  Interactive Data
05/10/2021 8-K Quarterly results
04/27/2021 8-K Quarterly results
01/07/2021 8-K Quarterly results
12/11/2020 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits  Interactive Data
12/09/2020 8-K Other Events
06/18/2020 8-K Submission of Matters to a Vote of Security Holders
06/12/2020 8-K Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S...
Docs: "Supplemental Indenture, between Rocket Pharmaceuticals, Inc. and Wilmington Trust, National Association, as trustee"
06/08/2020 8-K Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Regulation FD Disclosure, Financial Stat...
Docs: "NEW YORK – June 8, 2020"
04/22/2020 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
02/20/2020 8-K Quarterly results
02/11/2020 8-K Quarterly results
12/13/2019 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits
Docs: "Underwriting Agreement, among Rocket Pharmaceuticals, Inc., J.P. Morgan Securities LLC, Cowen and Company, LLC and Evercore Group L.L.C",
"Opinion of Orrick, Herrington & Sutcliffe LLP"
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy